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Abstract 
Rationale: Exercise capacity predicts mortality in pulmonary arterial hypertension but limited 
data exist on the routine use of maximal exercise testing. 
Objectives: This study evaluates a simple to perform maximal test, the incremental shuttle 
walking test, and its utility in risk stratification in pulmonary arterial hypertension (PAH).  
Methods: Consecutive patients with pulmonary hypertension were identified from the ASPIRE 
registry (2001-2018). Thresholds for levels of risk were identified at baseline, tested at follow-
up and incorporation into current risk stratification approaches assessed.
Results: Of 4524 treatment-naïve patients with pulmonary hypertension who underwent 
maximal exercise testing 1,847 patients had PAH. A step-wise reduction in one-year-mortality 
was seen between levels 1 (≤30m; 32% mortality) and 7 (340-420m; 1% mortality) with no 
mortality for levels 8-12 (≥430m) in idiopathic and connective tissue disease related PAH. 
Thresholds derived at baseline of ≤180m (>10%; high-risk), 190-330m (5-10%; intermediate-
risk) and ≥340m (<5%; low-risk of one-year mortality) were applied at follow-up and also 
accurately identified levels of risk. Thresholds were incorporated into the REVEAL 2.0 risk score 
calculator and French low-risk approach to risk stratification and distinct categories of risk 
remained. 
Conclusion: We have demonstrated that maximal exercise testing in PAH stratifies mortality-
risk at baseline and follow-up. This study highlights the potential value of the incremental 
shuttle walking test as an alternative to the 6-minute-walk-test, combining some of the 
advantages of maximal exercise testing whilst maintaining the simplicity of a simple to perform 
field test.
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Pulmonary arterial hypertension (PAH) is a life-shortening condition and risk stratification is 
recommended to guide treatment decisions. Exercise limitation is an early presenting symptom 
in PAH and measures of exercise capacity are typically severely reduced (1, 2). Exercise testing 
is recommended as part of a multi-parameter assessment in the European Society of Cardiology 
(ESC)/European Respiratory Society (ERS) and REVEAL 2.0 risk scores, and has been frequently 
used as an end-point in clinical trials (3, 4).
The six-minute walking test (6MWT) is the most widely used exercise test in pulmonary 
hypertension, and is inexpensive and simple to perform (5, 6). Absolute 6MWT distance 
(6MWD) correlates with haemodynamic parameters in idiopathic pulmonary arterial 
hypertension (IPAH) and predicts survival at baseline and follow-up (7-10). Nonetheless there 
are concerns about a ceiling effect above a distance of 450m, and younger patients with severe 
disease may walk beyond 500m (11-14). In addition, improvement of 6MWD in response to 
treatment has not been found to be independently prognostic in PAH (13, 15). 
Cardiopulmonary exercise testing (CPET) is a maximal test and provides comprehensive 
evaluation of multi-organ response to physical effort. Parameters from CPET are associated 
with prognosis in PAH but its utility in routine clinical practice may be limited by cost, 
complexity and duration of procedure (16).
The incremental shuttle walking test (ISWT) is an alternative maximal test for assessing 
patients with PAH, and is used in other forms of cardiac and respiratory disease (17-19). 
Previous studies have demonstrated correlation between ISWT distance (ISWD) and 
haemodynamic parameters at right heart catheterisation (RHC), and have confirmed that 
baseline and follow-up distances predict survival in PAH (20). The ISWT has potential 
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advantages over the 6MWT in that it does not suffer from a ceiling effect, potentially allowing 
better assessment in patients who are younger or have less severe disease (20, 21). Given these 
recognised limitations of the 6MWT, we sought to evaluate whether the ISWT could be used to 
risk stratify patients with PAH. The aim of this study was to assess whether thresholds could be 
identified for the ISWT and implemented into widely-used risk stratification scores.
Methods
Patients were identified from the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension 
Identified at a Referral Centre) registry, diagnosed with pulmonary hypertension between 1st 
February 2001 and 31st May 2018. Patients underwent multi-modality assessment as previously 
described (22). Data were collected prospectively and patients were required to have an ISWT 
performed at time of PH diagnosis, prior to commencement of PAH therapy. Patients with 
idiopathic, drug and heritable PAH were grouped and referred to hereafter as IPAH. Patients 
with IPAH and PAH related to connective tissue disease (PAH-CTD) typically represent the 
majority of patients with PAH in registry studies and patients in these groups were therefore 
used to establish and test thresholds (23-25). Thresholds for low, intermediate and high-risk of 
one-year mortality were defined as <5%, 5-10% and >10%, respectively, and were identified in 
incident, treatment-naïve patients based on one-year mortality (or need for lung 
transplantation) for each level. Thresholds were evaluated at follow-up, defined as the first 
reassessment beyond 90 days after commencing treatment. For the 6MWT it is recognised that 
younger patients with severe disease may walk low-risk distances of >500m, therefore in the 
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present study a sensitivity analysis was performed on patients aged <50 to assess whether the 
thresholds remained valid in stratifying risk in younger patients (12, 26).
Incremental Shuttle Walking Test
The ISWT was undertaken as described by Singh et al (27), and as part of the standard patient 
evaluation. Patients complete a 10m length keeping in time to an external audible signal. Level 
one consists of 3 lengths (30m) and each subsequent level adds one extra length to the 
preceding level. The initial speed is a slow walk, 0.50m/s, increasing incrementally every level to 
a maximum of 2.37m/s at level 12. Each level takes one minute to complete and the test 
finishes at the end of level 12, a distance of 1020m. The patient continues until they are too 
breathless or unable to keep up with the required pace (see table 2 for details of walking 
speeds). Patients who were unable to perform an ISWT due to breathlessness were ascribed an 
ISWT distance of 0m.
Mortality Data
Mortality data were obtained from the nationally-reported NHS Personal Demographics 
Service, updated when a death is registered in the UK, and transplant data were obtained from 
local databases. Patients who emigrated (n=3) were excluded from the study, as were patients 
not linked to a record on the Personal Demographics Service (n=2). The outcome assessed was 
transplant-free survival and census date was 31st May 2019, providing at least one-year of 
follow-up for all patients.
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Statistical Analysis
Statistical analysis was performed using SPSS v25 (IBM, Chicago) and GraphPad Prism v8. 
Continuous data were displayed as either mean ±SD or median (first quartile, third quartile) for 
non-parametric data. Demographics were compared using paired and unpaired T-test for 
parametric data, and Wilcoxon signed-rank and Mann-Whitney U-tests for non-parametric 
data. Frequencies were compared using Χ2. A p value of <0.05 was considered significant. 
Kaplan-Meier survival curves were compared using log rank Χ2. From receiver operating 
characteristic (ROC) analysis, a c-statistic was produced to compare variations on risk scores. 
Where ISWT levels demonstrated one-year mortality of 0%, these levels were combined for 
Kaplan Meier analysis and correlation with haemodynamics.
Ethics
Approval by the relevant ethics committee was sought and gained (STH14169, NHS Research 
Ethics Committee 16/YH/0352), and written consent was waived.
Results
A total of 4524 treatment-naïve patients with pulmonary hypertension, who had undergone 
ISWT at the time of diagnosis, were identified from the ASPIRE registry. Baseline characteristics 
for different forms of pulmonary hypertension are displayed in online data supplement Table 
E1. Of these, 1240 had either IPAH or PAH-CTD; table 1. Kaplan Meier analysis for ISWD in all 
forms of PH and for IPAH/PAH-CTD at baseline are displayed in figure 1.  
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IPAH and PAH-CTD
Incident, treatment naive patients with IPAH (n=603) had significant disease at right heart 
catheterisation, with a median mPAP 52mmHg, pulmonary vascular resistance (PVR) 10.5 WU 
and cardiac index 2.2 l/min/m2. Patients with PAH-CTD (n=637) had a median mPAP 43mmHg, 
PVR 7.3 WU and cardiac index 2.6 l/min/m2. The majority of patients received either 
combination oral treatment or treatment including a prostanoid. 
Within one-year of diagnosis, 197 patients (15.4%) with IPAH and PAH-CTD had died or 
undergone transplantation. Levels of the ISWT demonstrated an inverse relationship with risk 
of one-year mortality (Table 2). Patients who walked 0-30m had a one-year mortality of 32%. A 
step-wise reduction in percentage-mortality was seen at each level until a distance of ≥430m 
where there was a 0% mortality. Assignment of risk categories required concordance for both 
IPAH and PAH-CTD (Table 2). A high-risk of one-year mortality (>10%) was therefore defined as 
a distance of ≤180m, low-risk (<5%) as an ISWD ≥340m and intermediate-risk 190-330m. 
Corresponding values for cardiac MRI and pulmonary haemodynamic parameters are displayed 
in table 3. A stepwise reduction in right ventricular end-systolic volume index (%predicted) was 
seen with each level of the ISWT. When comparing baseline haemodynamic parameters 
between patients completing level 1 (≤30m) and level 2 (40-70m) of the ISWT, there were 
significant differences in mean right atrial pressure, cardiac index and mixed venous oxygen 
saturation (p all <0.05). 
At follow-up ISWT the thresholds accurately identified patients at low, intermediate and 
high-risk in the combined IPAH and PAH-CTD cohort (one-year survival 97%, 94%, 78%, 
respectively), and in the individual disease groups. Kaplan Meier graphs showing five-year 
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transplant-free survival at baseline, follow-up and demonstrating risk transition are displayed in 
figure 2. 
Age <50 Years
Using the above thresholds in incident patients aged <50, 30% were identified as low-risk and 
had 0% one-year mortality. Seventy patients (28%) were intermediate risk where observed one-
year mortality was lower than expected at 3%, whereas 42% of patients were high-risk and had 
a one-year mortality of 15%. A scatterplot showing baseline and follow-up distances and one-
year mortality is shown in the online data supplement (Figure E1).
Treatment Response 
Baseline median ISWD was 110m (40, 220) and paired tests at follow-up were available for 879 
patients. At follow-up, 132 (15%) patients had improved their ISWT risk-category (i.e. had 
improved to either intermediate or low-risk distance) and 83 (9%) had deteriorated. A 
scatterplot demonstrating individual baseline and follow-up distance is displayed in Figure 3. At 
paired testing, a median improvement of +10m (-30, +50; p<0.0001) was seen overall. Patients 
who achieved at least one ISWT level higher than at baseline (n=329, 37%), and therefore 
achieved a higher velocity, had significantly better 1 and 5-year survival (90% and 54%, 
respectively) than those who either remained in the same level (n=314, 36%; 1 and 5-year 
survival 84% and 37%; p<0.0001) or deteriorated (n=236, 27%; 1 and 5-year survival 79% and 
36%; p<0.0001), while there was no significant survival difference between those who were 
stable or deteriorated (p=0.61; figure 2). 
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Use in Conjunction with Risk Stratification Scores
Patients with baseline RHC data available including mean right atrial pressure (mRAP) and 
cardiac index (n=1076) were selected to assess whether ISWD thresholds could be used in 
conjunction with other risk stratification scores, in place of 6MWD thresholds. For the FPHR 
low-risk invasive approach to the ESC/ERS guidelines, a low-risk 6MWD of >440m was 
substituted with a low-risk ISWD of ≥340m. Survival differed significantly based on the number 
of low-risk criteria (0-4) between all groups (p<0.05) and at ROC analysis produced a c-statistic 
of 0.61 (95% CI 0.57-0.66), which was unchanged when used in the IPAH group in isolation, and 
higher than when the FPHR approach was used without any walking test (c-statistic 0.59; 95% 
CI 0.55-0.64). Kaplan Meier analysis for an abbreviated three-category risk score (3 or 4 criteria 
= low-risk, 1 or 2 criteria = intermediate-risk, 0 criteria = high-risk) is displayed in figure 4a, 
demonstrating separation of curves for each risk category (p all <0.0001). Using this three-
category FPHR risk score, low and high-risk groups were accurately identified (one-year survival 
96% and 78%, respectively) but risk in the intermediate group was underestimated (one-year 
survival 87%). 
When assessing the REVEAL 2.0 score in the same population, three variations for 
substituting 6MWD with ISWD were derived based on i) thresholds similar to the 6MWD 
thresholds used in REVEAL 2.0; ii) thresholds of low, intermediate and-high risk identified at 
baseline; and iii) thresholds of low, intermediate and-high risk identified at baseline with an 
extra point addition or deduction for very-high (≤30m) and very-low risk (≥430m), respectively, 
derived from baseline data shown in table 2. The REVEAL 2.0 c-statistic for one-year mortality 
without a walking test was 0.66 (95% CI 0.62-0.70); including ISWD thresholds from variation iii 
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produced a c-statistic of 0.71 (95% CI 0.67-0.75), compared to 0.69 for variations i and ii. Low 
(≤6), intermediate (7-8) and high-risk (≥9) REVEAL 2.0 scores (scores grouped as previously 
described (28)) accurately predicted one-year mortality; survival curves are displayed in Figure 
4, and detailed analysis of one-year mortality for REVEAL 2.0 scores are displayed in Figure 5. In 
all variations, patients with a REVEAL 2.0 score ≤6 had a 0% one-year mortality, and patients 
with a REVEAL 2.0 score of ≥9 had a one-year mortality of 19-20%. 
Discussion
In a large cohort of patients with IPAH and PAH-CTD we have demonstrated that routine use of 
maximal exercise testing can risk stratify patients into low, intermediate and-high risk of one-
year mortality/lung transplantation. Using a three-level risk score we have identified ISWT 
thresholds at baseline, shown the clinical utility in conjunction with other risks stratification 
scores and demonstrated that thresholds identified at baseline risk-stratify patients at follow-
up. 
Exercise capacity is recognised as an important physiological marker in PAH, and as a 
validated measure, the 6MWT has been the mainstay of exercise testing in PAH both in routine 
practice and in clinical trials (9). In early studies assessing PAH therapies, 6MWD was 
demonstrated to be a marker of treatment response (29). Absolute distances are prognostic, 
and deterioration of 6MWD is strongly associated with poor prognosis (15, 30). Despite this 
there has been criticism of the 6MWT, particularly over its role as an endpoint in clinical trials 
(13, 31), as prospective and retrospective studies have been unable to demonstrate that 
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improvements in 6MWD are independently associated with survival (15, 30). Furthermore, it is 
a submaximal test and may suffer from a ceiling effect, potentially limiting its use in younger 
patients or those with mild disease (32). 
We have previously shown that, as an alternative but maximal field walking test, the 
ISWT provides a measure of maximal exercise capacity without a ceiling effect and can identify 
exercise limitation in asymptomatic patients diagnosed with pulmonary hypertension in WHO 
FC I (20, 33). Using data from the present study we have now identified that maximal exercise 
testing using the ISWT can risk-stratify patients with IPAH and PAH-CTD. At baseline, in incident 
and treatment naïve patients, levels of the ISWT demonstrated good separation for both one-
year and longer-term survival. As a risk stratification tool, thresholds established at baseline 
were applicable at follow-up. As has been demonstrated with other prognostic investigations 
and risk stratification tools, patients who improved their risk profile demonstrated comparable 
longer-term survival to patients originally displaying that level of risk (24, 34, 35). 
A drawback of the 6MWT is that it suffers from a ceiling effect, whereby patients who 
walk >450m at baseline may not improve their walking distance in response to treatment 
despite improvements in WHO functional class and haemodynamics (20). In this study we have 
shown that, even amongst patients who walked ≥340m at baseline and remained in the low-
risk group at follow-up, 63% improved absolute ISWD in response to treatment. At higher 
follow-up distances of ≥430m and ≥530m, 68% and 69% of patients, respectively, were able to 
improve their ISWD after commencing treatment. A further criticism of the 6MWT is that 
younger patients with severe PAH, and therefore at high-risk of mortality, may still be able to 
walk distances >500m (12). We have therefore undertaken an exploratory analysis on patients 
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aged <50 and identified no mortality at one year for patients with a low-risk ISWT distance of 
≥340m.  
We have also demonstrated that patients who were able to achieve a higher ISWT level 
had significantly better long-term survival than patients who either remained in the same level 
or achieved a lower level at follow-up. This is expected as each level of the ISWT requires a 
higher maximal walking or running velocity, which has been shown to correlate with maximal 
oxygen intake (peak VO2) in other cardiorespiratory diseases (18, 19, 36). Peak VO2 has been 
identified as a strongly prognostic marker of survival in PAH when measured by incremental 
CPET (37), and other centres have confirmed the value of incremental exercise testing in the 
assessment of patients with pulmonary hypertension (38). 
Associations between incremental exercise testing and haemodynamics have been 
shown previously, and we have expanded upon this by showing association between this 
incremental test and important prognostic parameters from cardiac MRI with a stepwise 
reduction in right ventricular end-systolic volume %predicted with each level of the ISWT  (20, 
35, 38).
Our data demonstrate that ISWT thresholds can now be considered for incorporation 
into widely-used risk stratification tools. Using the French low-risk invasive approach to risk 
stratification, substitution of the 6MWT distances with equivalent distances for low, 
intermediate and high-risk from the ISWT continued to show five distinct risk groups at survival 
analysis. When combined into a three-category risk score, patients at low (3 or 4 criteria) and 
high-risk (0 criteria) had a one-year mortality of 4% and 22%, respectively. Boucly et al. noted 
the difficulties of defining an intermediate-risk group and we found that the presence of one or 
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two low-risk criteria underestimated one-year mortality, which was also seen when this 
approach was applied to the REVEAL population (25, 28). The c-statistic of 0.61 in our 
population of patients with IPAH is similar to that identified when the French approach was 
tested in the REVEAL registry (0.62), although no c-statistic is provided in the original research 
(25, 28).
In the REVEAL 2.0 risk score we have shown that when 6MWT distances are substituted 
with variations of ISWT thresholds, a three-level risk score accurately predicts one-year 
mortality in this population. The c-statistic of 0.71 is lower than that identified in REVEAL 2.0 
(0.76), and this may be the result of a phenotypically-different PAH population. In our study we 
included only patients with IPAH and PAH-CTD rather than other forms of PAH such as 
congenital heart disease (CHD). Furthermore, in our study, risk stratification approaches were 
applied to treatment-naïve patients rather than a mixture of incident and prevalent patients as 
in the REVEAL study. These factors, and particularly the absence of patients with PAH-CHD (the 
presence of which scores -2 points in REVEAL 2.0) may also explain why a relatively small 
number of our patients were identified as being at low-risk by REVEAL 2.0 when compared to 
the original study and external validation studies (28, 39).
Limitations
Distances achieved at 6MWT and ISWT are not directly comparable, and the thresholds used in 
this study were identified from baseline data. While we have assessed and confirmed that these 
thresholds remain valid at follow-up, as in any single-centre study both the thresholds and their 
role in risk stratification tools require prospective validation in a separate population. Although 
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we are unable to directly compare sensitivity and specificity for 6MWT and ISWT thresholds in 
the same population, our data support the use of the ISWT as a tool in risk stratification in PAH. 
In this study we have focused on patients with IPAH and PAH-CTD and further work is required 
to assess whether these thresholds remain valid in patients with other forms of PAH. All-cause 
mortality or transplantation was used as the primary end-point, and patients may have died 
from causes unrelated to PAH. Follow-up data were unavailable for 29% of patients, although a 
proportion of these patients did not survive to follow-up (15.4% died within one year of 
diagnosis). These missing data do not include patients who attended clinic but were unable to 
perform the ISWT due to breathlessness as these patients were assigned a distance of 0m. 
Finally, while the thresholds identified a large proportion of patients at high-risk of one-year 
mortality, this may reflect a high-risk population as demonstrated by the large number of 
patients with a high REVEAL 2.0 score with a corresponding one-year mortality of around 20%. 
The ISWT is simple to perform, and in contrast to the 6MWT requires a 10m rather than 30 m 
corridor, with an average time to complete the test of around 3 minutes, making it 
straightforward to incorporate into clinical practice.
Conclusion
Maximal exercise testing can be used to risk stratify patients with pulmonary hypertension 
including IPAH and PAH-CTD, and this study supports the routine use of maximal exercise 
testing in conjunction with other risk stratification tools. This study highlights the potential 
value of the incremental shuttle walking test as an alternative to the 6-minute-walk-test, 
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combining some of the advantages of maximal exercise testing whilst maintaining the simplicity 
of a simple to perform field test.
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Table 1: Baseline demographics in patients with IPAH and PAH-CTD
IPAH & PAH CTD IPAH PAH-CTD
n= 1240 603 637
Female (%) 71 61 80
Age 64 (53, 72) 62 (47, 72) 66 (57, 73)
WHO FC I (%) 0 0 0
WHO FC II (%) 13 13 13
WHO FC III (%) 63 59 67
WHO FC IV (%) 23 27 19
BMI (kg/m2) 27 (23, 31) 28 (24, 33) 26 (22, 30)
mRAP (mmHg) 9 (6, 14) 11 (7, 15) 8 (5, 12)
mPAP (mmHg) 48 (40, 56) 52 (46, 60) 43 (34, 51)
PAWP (mmHg) 10 (8, 13) 11 (8, 13) 10 (7, 12)
PVR (WU) 9.1 (5.7, 13.2) 10.5 (7.8, 14.5) 7.3 (4.7, 11.7)
SvO2 % 63 (56, 69) 61 (55, 67) 65 (58, 71)
Cardiac Output (l/min) 4.3 (3.2, 5.1) 4.0 (3.2, 5.0) 4.4 (3.4, 5.3)
Cardiac Index 
(l/min/m2)
2.4 (1.9, 2.9) 2.2 (1.8, 2.7) 2.6 (2.0, 3.1)
ISWD (m) 110 (40-220) 120 (40-260) 100 (40-195)
Treatment (%)
None or CCB 2 3 1
Oral mono 33 27 38
Combo oral 42 43 41
Prostanoid +/- oral 23 27 20
Continuous data were non-parametric and are presented as median (1st quartile, 3rd quartile).
Abbreviations: IPAH = idiopathic pulmonary arterial hypertension; PAH-CTD = pulmonary arterial 
hypertension related to connective tissue disease; WHO FC = World Health Organisation 
Functional Class; BMI = body mass index; mRAP = mean right atrial pressure; mPAP = mean 
pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; PVR = pulmonary 
vascular resistance; SvO2 = mixed venous oxygen saturations; ISWD = incremental shuttle 
walking test distance; CCB = calcium channel blockers.
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Table 2: Levels of the incremental shuttle walking test and associated mortality











Level 1 0-30m 0.50 267 (22) 31.8 23.4 40.8
Level 2 40-70m 0.67 206 (17) 18.5 11.0 24.3
Level 3 80-120m 0.84 196 (16) 15.3 12.4 17.8
Level 4 130-180m 1.01 172 (14) 14.5 15.2 14.2
Level 5 190-250m 1.18 137 (11) 9.5 4.5 14.1
Level 6 260-330m 1.35 110 (9) 4.5 5.5 3.6
Level 7 340-420m 1.52 69 (6) 1.4 2.3 0
Level 8 430-520m 1.69 52 (4) 0 0 0
Level 9 530-630m 1.86 18 (2) 0 0 0
Level 10 640-750m 2.03 9 (1) 0 0 0
Level 11 760-880m 2.20 2 (0) 0 0 -
Level 12 890-
1020m
2.37 2 (0) 0 0 -
*Each level has a duration of one minute. Abbreviations: ISWT = incremental shuttle walking 
test; IPAH = idiopathic pulmonary arterial hypertension; PAH-CTD = pulmonary arterial 
hypertension related to connective tissue disease; ISWD = incremental shuttle walking distance.
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Table 3: Association between ISWT level and haemodynamic and cardiac MRI parameters
Data are displayed as mean ±SD or median (first quartile, third quartile)
Abbreviations: ISWT = incremental shuttle walking test; MRI = magnetic resonance imaging; WHO 
FC = World Health Organisation Functional Class; mRAP = mean right atrial pressure; CI = cardiac 
index; SvO2 = mixed venous oxygen saturations; RVEF = right ventricular ejection fraction; RVESVi 








CI (l/min/m2) SvO2 (%) RVEF (%) RVESVi 
(%pred)
1 267 3.6 
±0.5
12 (8,16) 2.04 (1.67, 2.65) 58 (52, 66) 33 (27-42) 283 (225, 405)
2 206 3.3 
±0.5
10 (6, 15) 2.31 (1.80, 2.86) 61 (54, 67) 32 (25-44) 277 (163, 338)
3 196 3.1 
±0.5
10 (6, 14) 2.28 (1.81, 2.90) 62 (55, 69) 35 (24, 48) 253 (159, 371)
4 172 3.0 
±0.4
9 (6, 13) 2.40 (1.89, 2.9) 64 (58, 68) 35 (28, 43) 240 (162, 328)
5 137 2.9 
±0.5
8 (6, 13) 2.50 (2.00, 3.05) 66 (59. 70) 34 (25, 44) 237 (152, 328)
6 110 2.7 
±0.5
8 (5, 11) 2.60 (2.17, 3.20) 68 (63, 71) 36 (25, 48) 176 (132, 264)
7 69 2.6 
±0.5
9 (6, 12) 2.56 (2.20, 3.17) 66 (59, 71) 42 (34, 50) 183 (122, 258)
8-12 83 2.4 
±0.5
7 (5, 9) 2.85 (2.22, 3.22) 69 (63, 72) 40 (27, 48) 159 (120, 241)
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Figure Legends:
Figure 1: Kaplan Meier survival curves for a) ISWD in all PH; b) ISWD in IPAH and PAH-CTD. 
Abbreviations:  ISWT = incremental shuttle walking test; ISWD = ISWT distance; PH = pulmonary 
hypertension; PAH = pulmonary arterial hypertension; LHD = left heart disease; CTEPH = chronic 
thromboembolic pulmonary hypertension; IPAH = idiopathic pulmonary arterial hypertension; 
PAH-CTD = pulmonary arterial hypertension due to connective tissue disease
Figure 2: Kaplan Meier survival curves for a) ISWD risk groups at baseline; b) transition of ISWD 
risk groups between baseline and follow-up; c) comparison of patients who, at follow-up, 
achieved at-least one higher ISWT level, achieved the same ISWT level, or achieved a lower level 
than at baseline. Abbreviations: ISWT = incremental shuttle walking test, ISWD = incremental 
shuttle walking test distance
Figure 3:   A scatterplot showing individual baseline and follow-up ISWT distances, and mortality 
or transplant within one-year of follow-up ISWD in patients with idiopathic pulmonary arterial 
hypertension and pulmonary arterial hypertension due to connective tissue disease (n=879). 
Abbreviations: ISWD = incremental shuttle walking test distance
Figure 4: Kaplan Meier analysis demonstrating survival in: a) FPHR low-risk approach; b) REVEAL 
2.0 variation i (ISWD 0-180m = +1; 190-330 = 0; 340-420 = -1; ≥430m = -2 points); c) REVEAL 2.0 
variation ii (ISWD 0-180m = +1; 190-330m = 0; ≥340 = -1 point); d) REVEAL 2.0 variation iii (ISWD 
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0-30 = +2; 40-180 = +1; 190=330 = 0, 340-420 = -1; ≥430m = -2 points). Abbreviations: REVEAL = 
Registry to Evaluate Early and Long-Term PAH Disease Management, FPHR = French Pulmonary 
Hypertension Registry, ISWD = incremental shuttle walking test distance
Figure 5: Risk of mortality by REVEAL 2.0 score, using variations of REVEAL 2.0 incorporating 
ISWD as follows: REVEAL 2.0 variation I (ISWD 0-180m = +1; 190-330 = 0; 340-420 = -1; ≥430m = 
-2 points); REVEAL 2.0 variation ii (ISWD 0-180m = +1; 190-330m = 0; 340-420 = -1 point); 
REVEAL 2.0 variation iii (ISWD 0-30 = +2; 40-180 = +1; 190=330 = 0, 340-420 = -1; ≥430m = -2 
points). Abbreviations: REVEAL = Registry to Evaluate Early and Long-Term PAH Disease 
Management; ISWD = incremental shuttle walking test distance 
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Figure 1: Kaplan Meier survival curves for a) ISWD in all PH; b) ISWD in IPAH and PAH-CTD 
Abbreviations: 
ISWT = incremental shuttle walking test; ISWD = ISWT distance; PH = pulmonary hypertension; PAH = 
pulmonary arterial hypertension; LHD = left heart disease; CTEPH = chronic thromboembolic pulmonary 
hypertension; IPAH = idiopathic pulmonary arterial hypertension; PAH-CTD = pulmonary arterial 
hypertension due to connective tissue disease 
176x204mm (300 x 300 DPI) 
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Figure 2: Kaplan Meier survival curves for a) ISWD risk groups at baseline; b) transition of ISWD risk groups 
between baseline and follow-up; c) comparison of patients who, at follow-up, achieved at-least one higher 
ISWT level, achieved the same ISWT level, or achieved a lower level than at baseline. 
Abbreviations: ISWT = incremental shuttle walking test, ISWD = incremental shuttle walking test distance 
209x296mm (300 x 300 DPI) 
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Figure 3:   A scatterplot showing individual baseline and follow-up ISWT distances, and mortali  or 
transplant within one-ear of follow-up ISWD in patients with idiopathic pulmon a ri pertension and 
pulmona arterial hrrtension due to connective tissue disease (n=87
Abbreviations: ISWD = incremental shuttle walking test distance 
2	3
22mm (300 x 300 DPI) 
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Figure   Kaplan Meier anas demonstrating survival in: 
a) FPHR low-risk approach; 
b) REVEAL 2.0 variation i (ISWD 0-180m = +1; 190-330 = 0; 340-420 = -1; ≥430m = -2 points); 
c) REVEAL 2.0 variation ii (ISWD 0-180m = +1; 190-330m = 0; ≥340 = -1 point); 
d) REVEAL 2.0 variation iii (ISWD 0-30 = +2; 40-180 = +1; 190=330 = 0, 340-420 = -1; ≥430m = -2 
points) 
Abbreviations: REVEAL = Registry to Evaluate Early and Long-Term PAH Disease Management, FPHR = 
French Pulmonary Hypertension Registry, ISWD = incremental shuttle walking test distance 
232x181mm (300 x 300 DPI) 
Page 28 of 33
 ANNALSATS Articles in Press. Published September 14, 2020 as 10.1513/AnnalsATS.202005-423OC 
 Copyright © 2020 by the American Thoracic Society 
 
Figure  Risk o mortality by REVEAL 2.0 score, using variations o REVEAL 2.0 incorporating ISWD as 
ollows: 
REVEAL 2.0 variation I (ISWD 0-180m = +1; 190-330 = 0; 340-420 = -1; ≥430m = -2 points); 
REVEAL 2.0 variation ii (ISWD 0-180m = +1; 190-330m = 0; 340-420 = -1 point); 
REVEAL 2.0 variation iii (ISWD 0-30 = +2; 40-180 = +1; 190=330 = 0, 340-420 = -1; ≥430m = -2 points) 
Abbreviations: REVEAL = Registry to Evaluate Early and Long-Term PAH Disease Management; ISWD = 
incremental shuttle walking test distance 
108x28mm (300 x 300 DPI) 
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Online Data Supplement
Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk 
Stratify Patients with Pulmonary Arterial Hypertension
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Rothman MBChB, PhD; John Harrington; Neil Hamilton DPharm; Abdul G. Hameed PhD; A.A. 
Roger Thompson PhD; Athanasios Charalampopoulos MD; Charlie A. Elliot MD; Allan Lawrie 
PhD; Ian Sabroe PhD; Jim M. Wild PhD; Andrew J. Swift PhD; Robin Condliffe MD; David G. Kiely 
MD
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Table E1: Baseline demographics in all forms of pulmonary hypertension
All PH PAH PH-LHD PH-Lung  CTEPH Group 5
n= 4524 1847 988 766 791 129
Female (%) 61 69 66 46 50 60
Age 67 (56, 75) 63 (49, 71) 74 (67, 78) 68 (62, 75) 65 (53, 74) 62 (50, 70)
WHO FC I (%) 1 1 1 0 1 3
WHO FC II (%) 19 18 24 12 22 10
WHO FC III (%) 62 63 66 55 64 63
WHO FC IV (%) 18 19 9 33 13 23
BMI 28 (24, 33) 27 (23, 32) 30 (26, 35) 27 (24, 33) 28 (25, 33) 26 (22, 32)
mRAP (mmHg) 10 (7, 15) 9 (6, 14) 14 (11, 18) 9 (6, 13) 10 (7, 14) 10 (6, 14)
mPAP (mmHg) 44 (35, 52) 47 (37, 55) 38 (32, 46) 41 (33, 49) 46 (37, 53) 45 (35, 52)
PAWP (mmHg) 12 (9, 17) 11 (8, 14) 22 (19, 26) 12 (9, 15) 12 (9, 14) 12 (9, 14)






















































None or CCB 40 8 96 65 19 28
Oral 
monotherapy
34 38 4 29 68 38
Combo oral 17 36 0 5 7 23
Prostanoid +/- 
oral
9 18 0 2 5 12
Continuous data were non-parametric and are presented as median (1st quartile, 3rd quartile).
Abbreviations: PH = pulmonary hypertension; PAH = pulmonary arterial hypertension; PH-LHD = 
pulmonary hypertension due to left heart disease; PH-Lung = pulmonary hypertension due to 
lung disease; CTEPH = chronic thromboembolic pulmonary hypertension; WHO FC = World Health 
Organisation Functional Class; BMI = body mass index; mRAP = mean right atrial pressure; mPAP 
= mean pulmonary arterial pressure; PAWP = pulmonary arterial wedge pressure; PVR = 
pulmonary vascular resistance; SvO2 = mixed venous oxygen saturations; ISWD = incremental 
shuttle walking test distance; CCB = calcium channel blocker
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Figure E1: A scatterplot showing individual baseline and follow-up ISWT distances, and 
mortality or transplant within one-year of follow-up ISWD in patients aged <50 with 
idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension due to 
connective tissue disease 
Abbreviations: ISWT = incremental shuttle walking test, ISWD = incremental shuttle walking test 
distance
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Figure E1: A scatterplot showing individual baseline and fow-up ISWT distances, and mortality or 
transplant within one-year f follow-up ISWD in patients aged < with idiopathic pulmonary arterial 
hypertension and pulmonary arterial hypertension due to connective tissue disease 
Abbreviations: ISWT = incremental shuttle walking test, ISWD = incremental shuttle walking test distance 
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